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SUMMARY: 
It has been shown that Angiotensin-(1-7) [Ang-(1-7)] produces several effects 
related to glucose homeostasis. In this study, we aimed to investigate the 
effects of genetic deletion of Ang-(1-7), the GPCR Mas, on the glucagon –
producing cells. C57BL6/N Mas-/- mice presented a significant and marked 
increase in pancreatic α-cells (number of cells: 146±21 vs. 67±8 in WT - 
p<0.001) and the percentage per islet (17.9±0.91 vs. 12.3±0.9% in WT - 
p<0.0001) with subsequent reduction of β-cells percentage (82.1±0.91 vs. 
87.7±0.9% in WT - p<0.0001). Accordingly, glucagon plasma levels were 
increased (516.7 ± 36.35 vs 390.8 ± 56.45 pg/mL in WT, p<0.05) and insulin 
plasma levels were decreased in C57BL6/N Mas-/- mice (0.25 ± 0.01 vs 0.31 ± 
56.45 pg/mL in WT- p=0.02). In order to eliminate the possibility of a 
background-related phenotype we determined the number of glucagon-
producing cells in FVB/N Mas-/- mice. In keeping with the observations in 
C57BL6/N Mas-/- mice, the number and percentage of pancreatic α-cells were 
also significantly increased in these mice (number of α-cells: 260±22 vs. 156±12 
in WT, p<0.001; percentage per islet: 16±0.8 vs. 10±0.5% in WT, p<0.0001). 
These results suggest that Mas has a previously unexpected role on the 
pancreatic glucagon production. 
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 INTRODUCTION: 
Besides its role in the regulation of blood pressure and the 
cardiovascular system, the renin-angiotensin system (RAS) plays an important 
role in the control of glucose and lipid metabolism (1). Moreover, it is 
determinant in the pathophysiology of diabetes and metabolic syndrome (2). 
In the past few years, our understanding of the role of the heptapeptide 
Angiotensin-(1-7) has been extended to include other organs and systems well 
beyond the heart, vessels and the kidney (3). A relevant part of this new 
understanding is derived from the phenotypic characterization of Mas-deficient 
mice in a variety of models, tissues and conditions, including the cardiovascular 
system (4), liver (5), testis (6), memory process (7), erectile dysfunction (8) and 
inflammation (9,10).  
Angiotensin- (1-7) has been described to improve the glucose 
homeostasis by influencing different mechanisms including: improvement of 
insulin signaling in skeletal muscle (11), endothelium (12), adipose tissue and 
liver (13).  Moreover, Mas deletion has been reported to have deleterious 
effects on glucose and lipid metabolism (14). Although it is now clear, in 
contrast to ACE/Ang II/AT1R, the ACE2/Ang-(1-7)/Mas axis has a beneficial 
action on glucose metabolism (15, 16, 17, 18), the mechanism of the effect of 
Ang-(1-7)/Mas action regarding insulin-related mechanisms is not fully 
understood.  
In this study we aimed to further address this issue by determining the 
effect of Mas deletion on the α and β cell population in the pancreas. In order to 
rule out background dependency the study was performed in two mouse lines:  
C57BL6/N and FVB/N Mas-deficient (Mas-KO) mice. 
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RESEARCH DESIGN AND METHODS: 
Animals  
12 weeks-old male Mas-KO (both FVB/N and BL6/N, n=10) and Wild-Type (WT, 
n=8) mice, weighting approximately 25g, were obtained from the Biological 
Sciences Institute of Federal University of Minas Gerais (ICB-UFMG, Brazil). 
Mice were kept under standard and controlled environment conditions of 
temperature (20ºC - 25ºC), light and dark cycles (12 hours each, 06:00 - 18:00) 
with standard chow and water ad libitum. The experimental protocol was 
approved by the ethic committee in animal experimentation of Federal 
University of Minas Gerais (147/2008). 
 
Pancreas dissection and Immunohistochemistry 
After overnight fasting, mice were sacrificed by i.p. administration of a ketamine 
(130 mg/kg) and xylazine (0.3 mg/kg) solution. The pancreas was dissected and 
the splenic part was fixed in 10% formalin for 48hs, dehydrated in ethanol, and 
embedded in paraffin. Tissues were cut with 5 µm thick, with 150 µm interval 
between the cuts to obtain different pancreatic islets, and mounted on glass 
slides previously prepared to prevent detachment of cuts during the 
immunostaining. The slices were deparaffinized in xylene, rehydrated in alcohol 
baths decreasing concentration and washed in deionized water. Subsequently, 
the slices were processed for retrieving epitopes using the microwave oven in 
citric acid solution, pH 6.0 for 15 minutes. Next, the sections were treated with 
3% hydrogen peroxide (H2O2) for 30 minutes to inhibit endogenous peroxidase. 
The tissues were incubated with anti-glucagon primary antibody (1:200 – 
Abcam) at 4ᵒC overnight. The next day, the sections were incubated with the 
secondary antibody biotinylated (1:200 – Vector Laboratories) for 1 hour, and 
the slices were incubated with reagents of the ABC detection system, as 
specified by the manufacturer. Peroxidase activity was visualized by exposing 
the sections to DAB solution [(3-3)-diaminobenzidine tetrahydrochloride 
(Sigma)]. Thereafter, the sections were counterstained with Mayer hematoxylin 
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dehydrated in ethanol and mounted. In the negative control, the primary 
antibody was replaced by nonimmune serum. 
Glucagon Levels and Insulin: 
Enzyme-linked immunosorbent assay (ELISA) kit was used to measure serum 
insulin (Linco Research, St. Charles) and plasma glucagon (ALPCO 
immunoassays) levels. 
Image analysis: 
Positive immunostaining for pancreatic α-cell was examined using a light 
microscope (Zeiss). Ten islets per mouse pancreas were randomly chosen and 
all the cells present in the islet were counted. After that, each marked α-cell was 
also counted. The estimated β-cell content was obtained subtracting the total 
cells from the α-cells. 
Statistical Analysis 
Data were analysed using non-paired Student t test in the GraphPad 
Prism (GraphPad Software; San Diego, CA, USA).  Data are expressed as 
mean ± SEM and Statistical significance was accepted at the level of p<0.05.  
 
RESULTS 
As shown in Figure 1A, Mas-deficiency in the FVB/N background resulted in an 
increase in the total number and percentage of the pancreatic α-cell when 
compared to wild-type mice (number of α-cells: 260±22 vs. 156±12 in WT, 
p<0.001; percentage per islet: 16±0.8 vs. 10±0.5% in WT, p<0.0001).  Likewise 
the number and percentage of α-cells were significantly higher in the C57BL6/N 
in comparison to the WT mice (Figure 1B). The number of α-cells in C57BL6/N 
mice averaged is 146±21 vs. 67±8 in WT (p<0.001) and the percentage per islet 
is 17.9±0.91 vs. 12.3±0.9% in WT (p<0.0001). Regarding the estimated β-cell 
number, no significantly differences was evidenced in FVB/N and C57BL6/N 
mice, however, the percentage of β-cells was reduced in both backgrounds 
(C57BL6/N: 82.1±0.91 vs. 87.7±0.9% in WT p<0.0001; FVB/N: 83.53±1.2 vs. 
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88.6±0.9% in WT, p<0.001, Figure 2). No significant differences were observed 
in the total amount of cells in pancreatic islets, although a trend for increase in 
Mas-KO was observed (Figure 3). These results indicate that the increment in 
the total cell number, independently of the strain background, is linked to 
increase in the α-pancreatic cells. In keeping with the morphological data, 
glucagon plasma level was increased in C57BL6/N background: 516.7 ± 36.35 
vs 390.8 ± 56.45 in pg/mL vs WT 0.25 ± 0.01 vs 0.31 ± 56.45 pg/mL (p<0.05) 
while insulin 0.25 ± 0.01 vs 0.31 ± 56.45 pg/mL (p=0.02) in WT was reduced 
(Figure 4). 
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DISCUSSION 
In this study, we report for the first time that genetic ablation of Mas produced a 
marked alteration in the total number and percentage of glucagon-producing 
cell in the pancreas. This was associated to a significant increase of fasting 
plasma glucagon levels. As consequence of the increase of α-cells the 
percentage of β-cells was reduced in the pancreas since the absolute number 
did not differ from that of WT mice. In the past few years, the role of Ang-(1-
7)/Mas axis in the attenuation of metabolic diseases has been investigated in 
different models of diabetes and also in different experimental contexts (19,20). 
Wang and colleagues shed light on the pivotal role of ACE2/Ang-(1–7)/Mas axis 
in organogenesis during embryonic development of pancreatic islets. In this 
study, the authors also demonstrated a major role of Mas receptor in the 
pancreatic development and insulin secretion in early post-natal life reiterating 
the potential implications of the Ang-(1-7)/Mas axis for the development of 
therapies to handle pathological metabolic states (21).  
In keeping with of our current observation, we have previously described that 
Mas-KO mice presented significant changes in blood glucose homeostasis (14). 
In this previous study, however, we did not address the possibility of changes in 
glucagon as one of the mechanisms of such alterations. Although, functional 
studies involving glucagon-related mechanisms are obviously needed to fully 
understand its role in the metabolic changes observed in Mas-KO mice, our 
current data indicate that an imbalance of α and β cells is involved in the 
functional phenotypic changes of Mas-KO mice. 
In previous studies, significant differences were reported for the phenotypic 
variation in the two backgrounds where Mas has been deleted: FVB/N and 
C57BL6/N. For instance, increase in blood pressure was observed in FVB/N but 
not in C57BL6/N mice (22), and the metabolic syndrome-like state observed in 
FVB/N mice was absent in the BL6/N background (14). Here we show that the 
increase in glucagon-producing cells is a common feature of both backgrounds, 
clearly indicating that this phenotypic alteration is mostly linked to Mas deletion. 
A further implication of this finding is that Mas appears to play a key role in the 
glucagon-producing pancreatic cells. 
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Diabetes mellitus is characterized by insulin insufficiency due to either 
decreased insulin release or end-organ insulin resistance. Among the major 
existing categories of diabetes, type I (T1DM) usually occurs in children and 
young adults and is characterized by pancreatic β-cell failure or autoimmune 
destruction of the pancreatic β-cells (18). Indeed, it has been shown that 
glucagon antagonism, glucagon neutralizing antibodies and antisense 
oligonucleotides lower plasma glucose level in many rodent models of diabetes 
(23,24,25,26). Similarly, the reversal of diabetes induced by leptin therapy in 
rodents has been attributed to a reduction in plasma glucagon (27,28,29). In 
keeping with studies in rodents, suppression of glucagon in patients with 
diabetes improves glucose tolerance (30,31). These observations support a role 
for glucagon, and probably Mas, in diabetes hyperglycemia.  
 
CONCLUSION: 
The main finding of this report is the marked increase in the number and 
percent of pancreatic α-cells in Mas-deficient mice. This was associated to a 
significant increase in glucagon plasma levels. These findings suggest a crucial 
role for Mas in the pancreatic morphology with subsequent impact in glucose 
homeostasis. Although further studies are necessary to fully understand the role 
of Ang-(1-7)/Mas in the endocrine pancreas, our results provide a clear basis for 
understanding the role of Mas in glucagon production. 
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Figure 1A: Total number and percentage of pancreatic α-cells in FVB/N 
Mas-KO in comparison with WT mice; 
 
Figurre 1B: Total number and percentage of α-cells in C57BL6 Mas-KO 
mice vs. WT. 
 
1.A and 1.B:  Values are presented as means ± SEM Images represent the 
immunohistochemical staining of α-cell in mouse pancreatic islet of FVB/N and 
C57BL6 Mas-KO mice (A) Negative control: replacement of primary antibody 
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with buffer; (B) immuno staining for pancreatic α-cells in WT; (C) Mas-KO mice, 
respectively. Magnification: 40X. 
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Figure 2: 
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Figure 3:  
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Figure 4: 
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